The Latest Breaking News from GILD

The biotechnology sector has experienced extraordinary expansion, largely due to technological advancements that continue to position the industry as a pioneering influencer in crucial areas of healthcare, agriculture, and environmental stability. Given this backdrop, quality biotech stocks Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) could be solid…

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on.

As the biotech industry looks well-positioned for solid growth driven by strong government support and a growing foothold of personalized medicines, it could be wise for investors to buy fundamentally strong biotech stocks Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN). However, fundamentally weak Titan Pharmaceuticals (TTNP) might be best avoided.…

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

While macroeconomic uncertainties have fostered market volatility, the S&P 500 gained 7.8% year-to-date. We think fundamentally strong S&P 500 stocks Gilead Sciences (GILD) and Marathon Petroleum (MPC), which have gained more than 30% over the past year, could be worth buying now. Read more.

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading.

Coupled with macroeconomic headwinds, the sudden regional banking failures have marred investor sentiments. Moreover, amid anticipations of a recession, the existing market volatilities are not likely to subside anytime soon. Given this backdrop, we think the strong growth prospects of Gilead Sciences (GILD), Teva Pharmaceutical (TEVA), and MacroGenics (MGNX) make…

With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading.

With the broader market in trepidation amid the ongoing turmoil in the banking sector, fundamentally strong and resilient Nasdaq stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Autodesk (ADSK) could be worth investing in for sustained risk-adjusted returns. Continue reading….